Clinical Trials
173
Active:5
Completed:91
Trial Phases
6 Phases
Early Phase 1:7
Phase 1:18
Phase 2:28
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (140 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
73 (52.1%)Phase 2
28 (20.0%)Phase 1
18 (12.9%)Phase 4
11 (7.9%)Early Phase 1
7 (5.0%)Phase 3
3 (2.1%)Effectiveness of HabitWorks and Symptom Tracking for Anxiety and Depression
Not Applicable
Completed
- Conditions
- AnxietyDepression, Anxiety
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 340
- Registration Number
- NCT07025486
- Locations
- πΊπΈ
McLean Hospital, BElmont, Massachusetts, United States
Pharmacologic Augmentation of TMS for Depression With D-serine
Phase 1
Recruiting
- Conditions
- Depression
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06876129
- Locations
- πΊπΈ
McLean Hospital, Belmont, Massachusetts, United States
Stress Dynamics and Familial Risk for Depression in Female Adolescents
Not Applicable
Recruiting
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-10-23
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 148
- Registration Number
- NCT06816329
- Locations
- πΊπΈ
McLean Hospital, Belmont, Massachusetts, United States
Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans
Phase 2
Withdrawn
- Conditions
- Depression - Major Depressive DisorderAnxietyStress
- Interventions
- Drug: Nociceptin Receptor Antagonist (LY-2940094)Device: DS8R Biphasic Constant Current Stimulator
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06786637
Open Label Extension Study of NCT06221852
Not Applicable
- Conditions
- Bipolar I DisorderSchizoaffective DisorderPsychosis
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06558201
- Locations
- πΊπΈ
McLean Hospital, Belmont, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 35
- Next
News
First Patients Receive Groundbreaking Autologous Stem Cell Treatment for Parkinson's Disease in Phase 1 Trial
Mass General Brigham launches pioneering Phase 1 trial using patients' own reprogrammed stem cells to replace damaged dopamine neurons in Parkinson's disease, with three of six participants treated successfully.